Sold as Terramycin. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 16, 2026, FDA lists 7 applications for Oxytetracycline Hydrochloride (sold as Terramycin), first approved Sep 8, 1964, with 0 new uses approved and 0 published complete response letters.
| Jan 29, 1964 | Oxytetracycline HydrochlorideANDA 60869 | Proter | 0 | Discontinued |
| Sep 8, 1964 | TerramycinNDA 50286 | Pfizer | 0 | Discontinued |
| Aug 9, 1967 | Oxytetracycline HydrochlorideANDA 60760 | Impax Labs | 0 | Discontinued |
| Aug 11, 1967 | Oxy-Kesso-TetraANDA 60179 | Ferrante | 0 | Discontinued |
| Sep 29, 1967 | Oxytetracycline HydrochlorideANDA 60770 | Hikma | 3 | Discontinued |
| — | TerramycinANDA 60586 | Pfizer | 0 | Discontinued |
| — | Oxytetracycline HydrochlorideANDA 60634 | Purepac Pharm | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA